| XLS |
|
|
Merck Serono |
Consumer |
Pharmaceuticals |
Group/ | ||||||
|
€ million |
2008 |
2007 |
2008 |
2007 |
2008 |
2007 |
2008 |
2007 | ||
| ||||||||||
|
Sales |
4,649.6 |
4,187.0 |
439.9 |
418.2 |
5,089.5 |
4,605.2 |
7,201.6 |
6,775.1 | ||
|
Royalty income |
337.2 |
270.7 |
1.8 |
1.5 |
339.0 |
272.2 |
356.4 |
282.0 | ||
|
Total revenues |
4,986.8 |
4,457.7 |
441.7 |
419.7 |
5,428.5 |
4,877.4 |
7,558.0 |
7,057.1 | ||
|
Gross margin |
4,191.3 |
3,764.7 |
293.7 |
283.7 |
4,485.0 |
4,048.4 |
5,652.0 |
5,277.3 | ||
|
Selling. general and administration |
–1,958.9 |
–1,980.9 |
–213.4 |
–210.0 |
–2,172.3 |
–2,190.9 |
–2,712.9 |
–2,717.1 | ||
|
Research and development |
–1,074.4 |
–878.6 |
–16.8 |
–12.0 |
–1,091.2 |
–890.6 |
–1,234.4 |
–1,027.7 | ||
|
Operating result |
593.7 |
356.9 |
61.3 |
59.6 |
655.0 |
416.5 |
1,131.4 |
976.0 | ||
|
Exceptional items |
–354.0 |
–743.6 |
– |
– |
–354.0 |
–743.6 |
–400.0 |
–775.6 | ||
|
Earnings before interest and tax (EBIT) |
239.7 |
–386.7 |
61.3 |
59.6 |
301.0 |
–327.1 |
731.4 |
200.4 | ||
|
Net operating assets |
10,355.9 |
9,884.8 |
325.9 |
281.0 |
10,681.8 |
10,165.8 |
12,768.2 |
12,179.9 | ||
|
Segment liabilities |
–972.1 |
–799.0 |
–62.6 |
–54.5 |
–1,034.7 |
–853.5 |
–1,316.7 |
–1,128.0 | ||
|
Capital spending on property. plant and equipment |
235.4 |
147.6 |
14.1 |
6.1 |
249.5 |
153.7 |
394.7 |
263.3 | ||
|
Investments in intangible assets |
123.2 |
91.7 |
2.4 |
0.8 |
125.6 |
92.5 |
140.9 |
101.6 | ||
|
Net cash flows from operating activities |
926.8 |
875.9 |
45.6 |
50.9 |
972.4 |
926.8 |
1,024.0 |
1,181.4 | ||
|
Net cash flows from investing activities |
–373.1 |
–7,381.0 |
–40.0 |
–4.0 |
–413.1 |
–7,385.0 |
–81.7 |
–7,525.4 | ||
|
Free cash flow* |
553.8 |
–6,505.1 |
5.6 |
46.9 |
559.4 |
–6,458.2 |
438.4 |
–1,473.1 | ||
|
Impairment losses |
–338.8 |
–100.2 |
– |
– |
–338.8 |
–100.2 |
–345.6 |
–109.3 | ||
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
| ||
|
|
Liquid Crystals |
Performance & |
Chemicals |
Group/ | ||||||
|
in Mio € |
2008 |
2007 |
2008 |
2007 |
2008 |
2007 |
2008 |
2007 | ||
|
Sales |
864.6 |
909.4 |
1,240.9 |
1,231.3 |
2,105.5 |
2,140.7 |
7,201.6 |
6,775.1 | ||
|
Royalty income |
12.3 |
6.3 |
5.1 |
3.5 |
17.4 |
9.8 |
356.4 |
282.0 | ||
|
Total revenues |
876.9 |
915.7 |
1,246.0 |
1,234.8 |
2,122.9 |
2,150.5 |
7,558.0 |
7,057.1 | ||
|
Gross margin |
540.6 |
611.3 |
629.1 |
615.1 |
1,169.7 |
1,226.4 |
5,652.0 |
5,277.3 | ||
|
Selling. general and administration |
–61.4 |
–42.5 |
–401.4 |
–409.9 |
–462.8 |
–452.4 |
–2,712.9 |
–2,717.1 | ||
|
Research and development |
–84.8 |
–78.8 |
–58.4 |
–58.3 |
–143.2 |
–137.1 |
–1,234.4 |
–1,027.7 | ||
|
Operating result |
391.2 |
486.6 |
166.5 |
144.4 |
557.7 |
631.0 |
1,131.4 |
976.0 | ||
|
Exceptional items |
– |
– |
–46.0 |
– |
–46.0 |
– |
–400.0 |
–775.6 | ||
|
Earnings before interest and tax (EBIT) |
391.2 |
486.6 |
120.5 |
144.4 |
511.7 |
631.0 |
731.4 |
200.4 | ||
|
Net operating assets |
944.3 |
915.1 |
1,127.7 |
1,053.0 |
2,072.0 |
1,968.1 |
12,768.2 |
12,179.9 | ||
|
Segment liabilities |
–98.2 |
–90.0 |
–173.6 |
–176.9 |
–271.8 |
–266.9 |
–1,316.7 |
–1,128.0 | ||
|
Capital spending on property. plant and equipment |
64.5 |
48.6 |
78.9 |
57.9 |
143.4 |
106.5 |
394.7 |
263.3 | ||
|
Investments in intangible assets |
2.0 |
1.5 |
3.4 |
7.5 |
5.4 |
9.0 |
140.9 |
101.6 | ||
|
Net cash flows from operating activities |
472.7 |
474.0 |
146.5 |
181.1 |
619.2 |
655.1 |
1,024.0 |
1,181.4 | ||
|
Net cash flows from investing activities |
–70.6 |
–49.2 |
–88.8 |
–49.3 |
–159.4 |
–98.5 |
–81.7 |
–7,525.4 | ||
|
Free cash flow* |
402.1 |
424.8 |
57.7 |
131.8 |
459.8 |
556.6 |
438.4 |
–1,473.1 | ||
|
Impairment losses |
–0.6 |
–0.2 |
–6.1 |
–8.9 |
–6.7 |
–9.1 |
–345.6 |
–109.3 | ||
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
| ||
|
|
Corporate |
Discontinued |
Reversal Discontinued |
Group/ | ||||||
|
in Mio € |
2008 |
2007 |
2008 |
2007 |
2008 |
2007 |
2008 |
2007 | ||
|
Sales |
6.6 |
29.2 |
– |
1,391.8 |
– |
–1,391.8 |
7,201.6 |
6,775.1 | ||
|
Royalty income |
– |
– |
– |
2.7 |
– |
–2.7 |
356.4 |
282.0 | ||
|
Total revenues |
6.6 |
29.2 |
– |
1,394.5 |
– |
–1,394.5 |
7,558.0 |
7,057.1 | ||
|
Gross margin |
–2.7 |
2.5 |
– |
656.8 |
– |
–656.8 |
5,652.0 |
5,277.3 | ||
|
Selling. general and administration |
–77.8 |
–73.8 |
– |
–364.6 |
– |
364.6 |
–2,712.9 |
–2,717.1 | ||
|
Research and development |
– |
– |
– |
–95.3 |
– |
95.3 |
–1,234.4 |
–1,027.7 | ||
|
Operating result |
–81.3 |
–71.5 |
– |
188.7 |
– |
–188.7 |
1,131.4 |
976.0 | ||
|
Exceptional items |
– |
–32.0 |
– |
3,561.5 |
– |
–3,561.5 |
–400.0 |
–775.6 | ||
|
Earnings before interest and tax (EBIT) |
–81.3 |
–103.5 |
– |
3,750.2 |
– |
–3,750.2 |
731.4 |
200.4 | ||
|
Net operating assets |
14.4 |
46.0 |
– |
19.4 |
– |
–19.4 |
12,768.2 |
12,179.9 | ||
|
Segment liabilities |
–10.2 |
–7.6 |
– |
–7.5 |
– |
7.5 |
–1,316.7 |
–1,128.0 | ||
|
Capital spending on property. plant and equipment |
1.8 |
3.1 |
– |
19.5 |
– |
–19.5 |
394.7 |
263.3 | ||
|
Investments in intangible assets |
9.9 |
0.1 |
– |
19.5 |
– |
–19.5 |
140.9 |
101.6 | ||
|
Net cash flows from operating activities |
–567.6 |
–400.5 |
– |
36.9 |
– |
–36.9 |
1,024.0 |
1,181.4 | ||
|
Net cash flows from investing activities |
490.8 |
–41.9 |
– |
4,797.9 |
– |
–4,797.9 |
–81.7 |
–7,525.4 | ||
|
Free cash flow* |
–580.8 |
–406.3 |
– |
4,834.8 |
– |
– |
438.4 |
–1,473.1 | ||
|
Impairment losses |
–0.1 |
– |
– |
– |
– |
– |
–345.6 |
–109.3 | ||